CITATION REPORT List of articles citing

Phosphodiesterase type 5 inhibitor Tadalafil increases Rituximab treatment efficacy in a mouse brain lymphoma model

DOI: 10.1007/s11060-014-1690-0 Journal of Neuro-Oncology, 2015, 122, 35-42.

Source: https://exaly.com/paper-pdf/62211901/citation-report.pdf

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
14	Phosphodiesterase type 5 and cancers: progress and challenges. <i>Oncotarget</i> , 2017 , 8, 99179-99202	3.3	28
13	Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents. <i>Ecancermedicalscience</i> , 2018 , 12, 824	2.7	24
12	Use of Phosphodiesterase 5 Inhibitors Is Associated With Lower Risk of Colorectal Cancer in Men With Benign Colorectal Neoplasms. <i>Gastroenterology</i> , 2019 , 157, 672-681.e4	13.3	17
11	Metastatic brain tumor models and drug brain penetration analysis. 2019 , 197-232		
10	Angiopep-2 conjugated nanoparticles loaded with doxorubicin for the treatment of primary central nervous system lymphoma. <i>Biomaterials Science</i> , 2020 , 8, 1290-1297	7.4	14
9	Prostate Cancer Cell Phenotypes Remain Stable Following PDE5 Inhibition in the Clinically Relevant Range. <i>Translational Oncology</i> , 2020 , 13, 100797	4.9	3
8	Repurposing of Phosphodiesterase-5 Inhibitors as Therapeutic Agents Against Human Gastric Cancer. SSRN Electronic Journal,	1	
7	Diketopiperazine-Based, Flexible Tadalafil Analogues: Synthesis, Crystal Structures and Biological Activity Profile. <i>Molecules</i> , 2021 , 26,	4.8	4
6	New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil. <i>Frontiers in Oncology</i> , 2021 , 11, 627229	5.3	7
5	New drugs are not enough-drug repositioning in oncology: An update. <i>International Journal of Oncology</i> , 2020 , 56, 651-684	4.4	22
4	How do phosphodiesterase-5 inhibitors affect cancer? A focus on glioblastoma multiforme <i>Pharmacological Reports</i> , 2022 , 1	3.9	O
3	Pros and Cons of Pharmacological Manipulation of cGMP-PDEs in the Prevention and Treatment of Breast Cancer <i>International Journal of Molecular Sciences</i> , 2021 , 23,	6.3	1
2	Integration of Transcriptomics and Metabolomics Reveals the Antitumor Mechanism Underlying Tadalafil in Colorectal Cancer. <i>Frontiers in Pharmacology</i> , 2022 , 13,	5.6	
1	Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders. 2023 , 63,		1